Gram-negative Bacterial Infection
Conditions
Keywords
Gram negative, bacteria, infection
Brief summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.
Detailed description
Single-center, randomized, placebo-controlled, double-blind study to determine the safety, tolerability and pharmacokinetic profile of compound in single and multiple doses in young healthy males.
Interventions
DRUGAN3365
LP, 600 mg vial; reconstituted in Normal Saline
DRUGPlacebo
0.9% sodium chloride for injection
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Young healthy males, 18-45 years (inclusive) of age * Healthy as judged by a responsible physician with no clinically significant abnormality * Surgically sterile OR agrees to abstain from sexual intercourse with a female partner OR agrees to use a condom and spermicide during sexual intercourse with a female partner who uses another form of contraception * Body weight above 50 kg (Body Mass Index between 19 and 30 kg/m2) * Non-smokers * Willing and able to comply with study instructions and commit to all follow-up visits * Ability to understand, agree to and sign the study Informed Consent Form (ICF)
Exclusion criteria
* History of serious adverse reactions or hypersensitivity to any drug; or who have a known allergy to any of the test product(s) or any components in the test product(s); or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure * Any clinically significant central nervous system, cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions * Abnormal physical findings of clinical significance at the screening examination or baseline * History of orthostatic hypotension * Clinically significant abnormal laboratory values * Presence or history of allergies requiring acute or chronic treatment * 12 lead ECG abnormalities * Major surgical interventions within 6 months of the study * Has a positive pre-study Hepatitis B surface antigen; positive hepatitis C (HCV) antibody or detectable HCV ribonucleic acid (RNA); or positive HIV antibody result * Use of prescription or non-prescription drugs * Has a history of regular alcohol consumption * Loss of 500 mL blood or more during the 3 month period before the study * People that follow vegetarian or vegan diet * Symptoms of a significant somatic or mental illness in the four week period preceding drug administration * History of drug abuse or dependence within 12 months of the study * The subject has a positive pre-study alcohol or urine drug screen * Concurrent participation in another drug or device research study or within 60 days of post participation in another drug or device study * Considered by the Investigator to be unsuitable candidate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical safety data from 12-lead ECG, clinical laboratory tests, urinalysis, injection site tolerability, spontaneous/elicited adverse event reporting, and vital signs (blood pressure, heart rate, respiratory rate) | Multiple time points up to 14 days |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of pharmacokinetic parameters to achieve appropriate exposure and estimate the dose proportionality | Multiple time points up to 14 days |
Countries
Australia
Outcome results
None listed